The UK R&D-based pharmaceutical industry says its support for the Department of Health’s plans to introduce generic substitution in England hinges on four conditions1.
The industry wants biosimilars and vaccines, for example, to be excluded from any new scheme and for the list of drugs suitable for substitution to be updated at least once a year...
Please login to read the full article.
